Pfizer Ltd. Technical Momentum Shifts to Bearish Amid Mixed Market Returns

Technical Trend Overview

Pfizer’s current price stands at ₹4,913.15, slightly up from the previous close of ₹4,868.35. However, the broader technical landscape suggests a weakening momentum. The weekly technical trend has deteriorated from mildly bearish to outright bearish, reflecting increased selling pressure. On the monthly scale, the trend remains mildly bearish, indicating that the longer-term outlook is still cautious but not yet decisively negative.

The daily moving averages reinforce this bearish sentiment, with the stock trading below key averages, signalling downward pressure in the short term. This alignment of daily moving averages below the price is often interpreted as a warning sign for potential further declines.

MACD and RSI Signals

The Moving Average Convergence Divergence (MACD) indicator presents a mixed but predominantly bearish signal. On a weekly basis, the MACD is firmly bearish, suggesting that momentum is favouring the downside. The monthly MACD, while mildly bearish, indicates that the longer-term momentum has yet to fully capitulate but remains under pressure.

Relative Strength Index (RSI) readings, however, do not provide a clear directional signal at either the weekly or monthly level. The absence of RSI extremes suggests that the stock is neither overbought nor oversold, leaving room for further movement in either direction depending on broader market catalysts.

Bollinger Bands and KST Analysis

Bollinger Bands, which measure volatility and price levels relative to recent averages, show a mildly bearish stance on the weekly chart and a more definitive bearish signal on the monthly chart. This indicates that Pfizer’s price is trending towards the lower band, often a sign of increased selling pressure and potential continuation of the downtrend.

The Know Sure Thing (KST) indicator, which aggregates multiple rate-of-change measures, aligns with this bearish narrative. Weekly KST readings are bearish, while monthly readings remain mildly bearish, reinforcing the view that momentum is weakening but not yet at a critical low.

Volume and Dow Theory Perspectives

On-Balance Volume (OBV) presents a nuanced picture. Weekly OBV is mildly bearish, indicating that volume trends are not strongly supporting price advances. Conversely, the monthly OBV is bullish, suggesting that longer-term accumulation may be occurring despite short-term selling pressure. This divergence between volume and price action warrants close monitoring as it could signal a potential reversal or consolidation phase.

Dow Theory assessments remain mildly bearish on both weekly and monthly timeframes, consistent with the overall cautious technical outlook. This theory, which emphasises the confirmation of trends through market averages, suggests that Pfizer’s stock is still in a downtrend but has not yet reached a decisive bottom.

Comparative Performance and Market Context

Pfizer’s recent returns have lagged behind the broader Sensex benchmark across multiple time horizons. Over the past week, Pfizer declined by 0.31% while the Sensex gained 0.46%. The one-month return shows a sharper underperformance with Pfizer down 1.64% against the Sensex’s 0.76% loss. Year-to-date, Pfizer’s return is -1.39%, compared to a marginal Sensex decline of 0.18%.

Longer-term comparisons reveal a more pronounced divergence. Over one year, Pfizer’s stock has fallen 4.55%, while the Sensex has risen 9.10%. Over three years, Pfizer has gained 13.40%, but this pales in comparison to the Sensex’s 42.01% rise. The five-year picture is even more stark, with Pfizer down 4.93% versus the Sensex’s 76.57% surge. Over a decade, Pfizer has delivered a respectable 108.88% return, yet this remains well below the Sensex’s 234.81% gain.

Price Range and Volatility

The stock’s 52-week price range spans from ₹3,742.90 to ₹5,987.65, indicating significant volatility within the past year. Today’s trading session saw a high of ₹4,927.55 and a low of ₹4,828.30, reflecting a relatively narrow intraday range but consistent with the broader bearish technical signals.

Mojo Score and Grade Implications

MarketsMOJO’s proprietary scoring system assigns Pfizer a Mojo Score of 43.0, placing it firmly in the Sell category with a Mojo Grade of Sell, downgraded from Hold on 29 December 2025. The Market Cap Grade stands at 3, signalling a mid-tier market capitalisation relative to peers. This downgrade reflects the deteriorating technical momentum and the cautious outlook from multiple indicators.

Investor Takeaway

Pfizer Ltd.’s technical indicators collectively point to a bearish momentum shift, with several key metrics signalling caution. The downgrade in mojo grade to Sell underscores the need for investors to reassess their positions, especially given the stock’s underperformance relative to the Sensex over multiple time frames.

While the absence of extreme RSI readings suggests the stock is not yet oversold, the alignment of bearish MACD, moving averages, and Bollinger Bands indicates that downward pressure may persist in the near term. The divergence between weekly and monthly OBV readings adds complexity, hinting at potential accumulation at longer timeframes but not enough to reverse the prevailing trend.

Investors should closely monitor upcoming earnings reports, sector developments, and broader market conditions that could influence Pfizer’s trajectory. Given the current technical setup and fundamental context, a cautious approach is advisable until clearer signs of trend reversal emerge.

Conclusion

In summary, Pfizer Ltd. faces a challenging technical environment as it transitions into a more bearish phase. The combination of deteriorating momentum indicators, relative underperformance, and a recent downgrade in mojo grade suggests that investors should exercise prudence. While the company remains a significant player in the Pharmaceuticals & Biotechnology sector, its stock price action and technical signals warrant careful analysis before committing fresh capital.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →